ALPHAMAB ONCOLO.DL-000002 - Asset Resilience Ratio

Latest as of December 2025: 52.05%

ALPHAMAB ONCOLO.DL-000002 (3NK) has an Asset Resilience Ratio of 52.05% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALPHAMAB ONCOLO.DL-000002 free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

€1.09 Billion

≈ $1.28 Billion USD Cash + Short-term Investments

Total Assets

€2.10 Billion

≈ $2.45 Billion USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how ALPHAMAB ONCOLO.DL-000002's Asset Resilience Ratio has changed over time. See 3NK equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down ALPHAMAB ONCOLO.DL-000002's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 3NK stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€1.09 Billion	52.05%
Total Liquid Assets	€1.09 Billion	52.05%

Asset Resilience Insights

Very High Liquidity: ALPHAMAB ONCOLO.DL-000002 maintains exceptional liquid asset reserves at 52.05% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

ALPHAMAB ONCOLO.DL-000002 Industry Peers by Asset Resilience Ratio

Compare ALPHAMAB ONCOLO.DL-000002's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for ALPHAMAB ONCOLO.DL-000002 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for ALPHAMAB ONCOLO.DL-000002.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	52.05%	€1.09 Billion ≈ $1.28 Billion	€2.10 Billion ≈ $2.45 Billion	+31.56pp
2024-12-31	20.49%	€459.35 Million ≈ $537.02 Million	€2.24 Billion ≈ $2.62 Billion	+5.46pp
2023-12-31	15.03%	€321.25 Million ≈ $375.57 Million	€2.14 Billion ≈ $2.50 Billion	+1.75pp
2022-12-31	13.28%	€281.19 Million ≈ $328.74 Million	€2.12 Billion ≈ $2.48 Billion	-30.42pp
2021-12-31	43.70%	€1.18 Billion ≈ $1.38 Billion	€2.71 Billion ≈ $3.16 Billion	--

pp = percentage points

About ALPHAMAB ONCOLO.DL-000002

F:3NK Germany Biotechnology

Market Cap

$866.26 Million

€740.96 Million EUR

Market Cap Rank

#9710 Global

#1185 in Germany

Share Price

€0.77

Change (1 day)

+1.32%

52-Week Range

€0.66 - €1.68

All Time High

€3.04